ClinicalTrials.gg

Program

KDT-3594

A development code.

Its studies are mostly in Parkinson Disease, led by Kissei Pharmaceutical.

Furthest: phase 2, since Feb 15, 20194 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kissei Pharmaceutical40 open or runningphase 2since Feb 15, 2019Feb 26, 2017none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 26, 2017First study: phase 1 study in Parkinson DiseaseFirst studyNCT03068481 · 36 enrolled · Japan
  2. Feb 15, 2019Phase 2 study in Parkinson DiseaseNCT03845387 · 74 enrolled · Japan
  3. Apr 27, 2021Phase 2 study in Parkinson DiseaseNCT04867551 · 7 enrolled · Japan
  4. Nov 26, 2024Phase 2 study in Parkinson DiseaseNCT06722729 · 178 enrolled · Japan

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06722729Parkinson Disease · Japan2CompletedJan 14, 2026178
NCT04867551Parkinson Disease · Japan2CompletedSep 6, 20217
NCT03845387Parkinson Disease · Japan2CompletedFeb 21, 202074
NCT03068481Parkinson Disease · Japan1CompletedAug 13, 201836

How it is read

Names in the registry

  • “KDT-3594”, 4 entries

Codes read as this program: KDT3594.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.